Rob Friel: Yes. We’re forecasting 4% is sort of mentioned previous year or Andy mentioned too. Is there a possibility we can do better than that? I think so. We’re seeing good trends in pharma as you pointed out. We continue to get good traction in our service business and food was very strong for us. So I think the key for fourth quarter and will be for 2018 the businesses that have been sort of our growth businesses that we focus on have continue to do well and are growing sort of high single low-double. The challenge in the first couple of quarters of the year was that the core – our core businesses were sort of flat low single-digit. What we saw in the fourth quarter was that the core businesses actually recovered in sort of mid single digits. If we continue to see that in the 2018 timeframe, I think DAS will do better than 4%.
Rob Friel: So EUROIMMUN continue to see strong growth in the fourth quarter – the entire year of 2017 and we sort of commented before. They continue to grow sort of at the high teen growth rate and it’s fairly broad based among the three businesses whether it’s autoimmune, allergy and infectious disease they all experience good growth. So we’re excited to see that. With regard to the operating margins of EUROIMMUN I think our approach right now is as we continue to see the volume ramp, we expect the margins to go up there. But for the immediate timeframe or at least for the short-term I think we’ll see that ramp maybe 100 basis points a year or something like that. So I don’t know that we’ve got huge expectations at least for the next couple of years to see significant ramping up of EUROIMMUN margins.
Rob Friel: Okay. First of all when we look at diagnostics the focus there has been sort of expanding our impact there. So I think I wouldn’t expect to see much on the divestiture side there on the diagnostic business, we just look to continue to sort of add our ability to impact by geographic region and the state. And I sort of alluded to that in my comment. I think in the DAS business again the majority of our focus is on how do we invest more in the growth areas. Because I think that’s really how ultimately we make that a better business. Having said that during the year could we see some product lines being shut I think we could but I wouldn’t say there are significant dollar amounts. But again I would say the majority of the focus on DAS is how do we make that business execute better. And then the second thing is focus on the areas where we have the most significant growth opportunities. But you should – you could see some, but I wouldn’t say it’s a significant number.
Rob Friel: I’ll answer that and Andy can handle the gross margin. I think – we think it’s prudent given the amount of potential disruption of a business that has been sort of privately run for over 30 years. And we’ve talked about before our goal is going to be to sort of do as little disruption is possible. We just think at this point as we sort of better understand the business that to take it down from call it 18% to something in the sort of 13% or 15% is prudent. Having said that I don’t know that there is anything either market or competitive wise that would suggest that we’re necessarily going to see a deceleration in growth but we just think for purposes of forecasting 2018 – we should lower the growth rate by a couple 100 basis points again just to be prudent.
Rob Friel: So we’ve been working with them we actually had a meeting earlier this week between the U.S. sales force and EUROIMMUN and PerkinElmer sales force. I think we’ve got a very good plan mapped out from the standpoint of educating both sales forces on each other’s products. I think we’ve got a good plan with regard to the specific customers that will target. We’ve actually got incentive plans in place for each company to sort of provide leads on for each other products and we start to put in the regulatory resources required to accelerate. Hopefully accelerate EUROIMMUN’s regulatory approvals of some of their products. So I think we’ve got a very good – hopefully accelerate the growth rate of EUROIMMUN in U.S. over the next couple of months or quarters.
Rob Friel: No. I think, if we get EUROIMMUN – when we talked about the previous discussion we’ve got that it’s sort of 13% to 15% this year if that continues to get in the high teens – as we start to get some of the traction with Vanadis, we get into 19% and 20%, we’ve seen initial good response on the genetic testing business. And of course, what we’re finding is increasing synergies between EUROIMMUN and tool as we look to penetrate some of the emerging areas. I mean there’s a number of levers that we feel like we should be able to get up into double digits from the diagnostic business.
Rob Friel: It’s fairly low, I would say because the timing of the tenders our expectations for Vanadis for 2018 at least in our plan is less than $10 million.
Rob Friel: So I think in genetic testing, we’ll sort of see that ramp to probably – again $5 million to $10 million business in 2018. And then by 2020 we’ve been saying that we think we can get up to closer to $50 million business particularly as we start to branch that out globally. Up to this point it’s largely been a U.S. business but our intentions are to move this out into India and China and some other areas as well, so call it maybe $10 million next year but $50 million by 2020.
Rob Friel: So first of all China continue to be strong for us in the fourth quarter. I think it was sort of mid-teens, give or take. And I think as we think about going into 2018 right now, I would say we’re forecasting in sort of the high-single low-double digit again mainly context of being low prudent year particularly on the EUROIMMUN side. EUROIMMUN has continued to see very strong growth in China. I would say when you look at our businesses, the diagnostic business has also done well particularly in the newborn and prenatal side. The one area where we’ve seen a little bit of a challenge has been in some of the tenders, the local content is becoming increasingly more important, in fact there are some tenders on the newborn side where we haven’t been able to bid on. And so probably it’s been 18 months now. We’ve been sort of aggressively moving our manufacturing of some of our assays, some of our instruments into China on the diagnostic sides. And of course some of that requires regulatory approval, so I would say I continue to be fairly bullish on the diagnostic side within China, but we’ve got to be able to make sure that our businesses and this is mostly on the reproductive health side are able to meet the local content requirement. When I go to sort of non-diagnostic at the DAS side, I think we continue to be enthused with the opportunities there whether it’s the environmental, whether it’s the pharmaceutical side. And I think we’ve seen some recovery on the industrial market if you sort of alluded to. So I think – and I think some of the benefits we’re seeing is that we’re trying to increasingly make sure that our products are designed and manufactured for those markets specifically. So whether it’s the functionality or whether it’s the cost position and I think we’re seeing good traction there.
Rob Friel: Yes. Maybe said little differently the way to think the growth rate by quarter doesn’t necessarily very much. So our assumption is the 13% to 15% is fairly consistent through the four quarters. The difference is the absolute number historically is low in the first quarter.
Rob Friel: So I’ll take the first one, so yes, $66 million is the total for the year and we were I think through the first three quarters you’re right, we’re sort of tracking to the low 50s. It just was a mix of revenue that we saw in the fourth quarter sort of less attributable to new products. And then I would say going into 2018, although you didn’t ask, we think $50 million is probably a good number as well. Now that would exclude EUROIMMUN. I would say at this point I don’t know that we’ve got good visibility in the split in the revenue growth between new products and sort of existing products, but we think we can do at least another $50 million next year as well.
Rob Friel: So I would say first of all, I don’t know that the strategy behind our capital deployment has changed, because of the EUROIMMUN acquisition. I think the preference would still be first acquisitions, bolt-on acquisitions in particular that sort of add capabilities either technological or others, then probably the second most area would be if share repurchased. And in probably third would be to continue to sort of reduce our debt to a level below let’s say two times EBITDA. If you look at the leverage we took on relative to the EUROIMMUN acquisition, we believe with the combination of the EBITDA growth and the cash we generate that we could delever relatively quickly. So the answer to your question relative to acquisitions we continue to have a fairly robust pipeline. We continue to sort of look at a lot of potential opportunity to buy things. I would say the only difference is probably in the short-term. I would say doing a large deal that I would say sort of north of $1 billion is unlikely, not impossible but unlikely. But I think we feel we can continue to do $100 million, $200 million, $300 million deals even the cash flow we generate. And like I said we believe we have the ability to delever relatively quickly. With regard to the second part of the question is to we have the portfolio currently to get the high-single digits for PerkinElmer. And I think so as we continue to migrate the portfolio organically and I think if you look at a couple years diagnostics will be a bigger component. I think the service component of DAS will be bigger. I think the food component of DAS will be bigger. And as I mentioned before maybe we will get out of a couple product line. But if we can add let’s say a $200 million of incremental profits in high growth areas, I think that would be helpful. But I don’t feel like we need to do a major transformational deal between now and 2020 to get the high-single digits. As we’ve spike that into past, we talk about 50% of our business has historically been growing close to 10%. So the idea is to continue invest in those areas make them bigger and we can get the high-single digit growth organically.
Rob Friel: Yes, okay. So if you look at pharma and the biotech areas, that was sort of a low double, actually, for us. So it was a nice step up. We were very pleased to see that. Food was high single. Environmental was actually sort of low double digits as well. Industrial was up high single. And the only one we saw a little bit of decline on was academic and government, which again, isn’t a big business for us, was down low single digits.
Rob Friel: Yes. I would say, for us when we look at the fourth quarter on our industrial side, we saw pretty good growth in the Americas and Europe. APAC was a little challenged. But I think, to a large extent, that was a difficult comparison year-over-year. So I think we support the view that the industrial market continue to be constructive. And I think as we project it into 2018, that’s the view that we continue to believe is the appropriate one.
Rob Friel: So China, actually, with EUROIMMUN right now, will take us through to over $600 million in revenue for PerkinElmer. So against a 2018 forecast of $2.7 billion, it’s almost between 20% and 25% of our revenue. So it’s increasingly becoming a more important part of us. To some extent, as I sort of alluded to on the diagnostics discussion earlier, I mean, that was part of our strategy. When you look at 40% of the population between China and India and 10% of the diagnostics spending, we do think that’s an area where you’re going to see disproportionate spending, so we like that aspect of it. Clearly, when you look at environmental and food, even on the pharmaceutical side, I think those are other areas that have been identified as key areas of investment by the government. So we continue to feel very good. We continue to invest there, whether it’s in people, whether it’s in manufacturing capability, whether it’s increasing our R&D. But – so we continue to be fairly bullish on the Chinese area now. I sort of alluded to before that probably relative to the growth we’ve seen historically, that may come down a little bit. But I think to some extent, we’re just getting such a large business there that I think we’re planning in the low double-digit growth in China, but I think that’s the realistic and prudent approach.
Rob Friel: Yes, absolutely. I mean, I think that’s an important part of the strategy in DAS is to continue to expand our consumable portion of the business, and then also continuing to use service that hopefully pull through more product. But the other aspect of service is continue to expand the types of services we provide. And then we also believe, when we get to maybe the 2020 time frame, again as our customers look to change the way they deploy technology that we make it into a situation where increasing more and more customers are looking to technology partners to provide measurements and outcomes as compared to product. And I think we’ll be in a very good position to do that. But the answer to your question is yes, absolutely. We want to try and improve the service software and consumable portion of the business that not only reduces or dampens down the cyclicality, as you point out, but also should translate into higher margins.
Rob Friel: Derik, maybe to sort of help clarify that is we have call it 35%, 40% of our revenue in the U.S. We have less than 15% of our profit in the U.S.
Rob Friel: And part of that was purposeful, right. So if you go back and think about 35% tax rate in the U.S. was – has been sort of publicized quite often as one of the highest in the developed world is you purposefully want to put a lot of your expenses there. So we had, like I said, less than 15% of our income in the U.S., at least from a tax perspective. And so therefore, the rate-down from 35% to 21% did not have that significant of an impact. And then some of the other provisions that are in the tax law are sort of slightly offsetting the impact of the lower rate.
Rob Friel: I think when you look at pharma product, again, up high single digits. The sense was there probably was some. It’s hard for us to tell right now. I would tell you that while we saw strong bookings in the end of the fourth quarter they’ve continued to some extent in January. But it did appear at least when we look at the numbers that clearly we saw a ramp up in orders and sales in the December timeframe. So my sense is that there was some budget flush.
Rob Friel: So initially, we were going to come out particularly focused on, I would say, a limited menu from the standpoint of the trisomies and then the sex chromosomes. So 13, 18, 21 and X and Y. Now we do think down the road we might be able to sort of expand upon that, but initially, that’s the focus.
Rob Friel: So with regard to the studies that we want to be sort of focused on was there’s a couple that are ongoing right now that are generating clinical data, and we would hope to see something like that maybe in the second quarter. With regard to blood screening, I think as we mentioned before, we had strong placement of instrument in the sort of – or particularly in the first half of 2016 that was causing some difficult comps earlier in the year. We continue to see good growth from the reagent side of things. So it generates a fair amount of profitability, but you’ll don’t see the impact on the revenue until we sort of cycle through the instrument placements that occurred in 2017 – or in 2016. So I think as we go into 2018, we expect to see some better growth from the blood screening business.
Rob Friel: So with regard to pricing, we’ll probably come out with the pricing when we release the product commercially, so after CE mark. And with regard to tender, yes, we have a very good perspective on which tenders, which countries, when they come out, and we’re focused on a couple more significant tenders that start sort of early second half. But yes, we have some fairly specific targets in mind. And so hopefully, we get the CE mark out in the latter half of Q2 and to be able to place. I think the goal is probably eight to 10 instruments in the back half of the year. And we’ll start to generate some reagents, but as I sort of alluded to before, I think the significant growth will probably be in the earlier part of 2019.
Rob Friel: I would say, I don’t know the number at top of my head. Probably mid-single, probably that type of rage, maybe six, if I had to guess.
Rob Friel: So Chelsea thank you, and thank all of you for your questions and interest in PerkinElmer. Looking ahead, I continue to be energized by our employees and the many opportunities we see to continue to drive our mission of innovating for a healthier world. I have no doubt this year we will once again successfully deliver on our commitments to our customers and shareholders. We feel very good about our plans moving ahead and look forward to updating you on our progress next quarter. Thanks, again, and have a terrific evening.
Andy Wilson: And Steve to answer your question on gross margin there wasn’t really anything similar in the period. What we have seen throughout 2017 was a bit of a mix shift into services, which obviously have an impact on gross margins. And in the mix we saw a strong growth within DAS which has lower margins than diagnostics and that also contributed to the margin performance. Although, as I mentioned in our prepared remarks, we think that as we move into 2018 we should be able to expand those gross margins at least 150 basis points. So I think we feel like we’re very situating go into 2018.
Andy Wilson: Yes. The anomaly – I’ll answer the second question first and then I’ll answer your first question second. The anomaly is really just the first quarter. So you’ll see, we’ve talked about the growth for the year and the first quarter as we said is seasonally low, Q2, Q3 and Q4 are fairly consistent with the fourth quarter being slightly higher than the second and third. So that’s the rate it’s been historically and that’s the way we’re planning to 2018. The split within the 9% is about 2.5 percentage points related to EUROIMMUN and in the core business is growing at about 6.5%.
Andy Wilson: And then as far as your question related to the compensation, we typically do not breakout compensation. This is a part of our longer-term compensation plan, what you can find in our proxy. So it’s something that’s been around and we felt like that it was really a part of the operating results and really didn’t need to be broken out in the box.
Andy Wilson: Where we – this has been our consistent long as I’ve been here, but we use the ending rate from the previous quarter. And so going into this year, we used $1.18 rate, which obviously, the euro has strengthened dramatically. We’ll obviously provide an update each quarter as we true that up. But we typically use that rate at the end of the previous quarter to establish our guidance for the next quarter.
Andy Wilson: Jack, on pharma and bio, the nice thing we saw here has typically been driven a lot by service. But we did see some pick up in product in the fourth quarter, which was encouraging.
Andy Wilson: All right, I’ll start. We haven’t seen a real significant impact on our tax rate from the comp piece. As we went into the year and started looking in 2018, we went through and determined that, as I mentioned on my – in my prepared remarks, we think that the changes coming up next year will be a modest headwind, and the real impact to our tax rate from 2017 to 2018 will be the mix in domicile profits which is primarily due to EUROIMMUN. So we said 18.5%, and that’s really – what the majority of that is a slight headwind on the Tax Act and a bigger headwind on the domicile profits.
Andy Wilson: That’s true, we had about $10 million expenses related to the deal cost on the EUROIMMUN transaction, which hit – all hit in the fourth quarter that were accrued pay. In addition, as we go into – I’m sorry, one of the thing is we also have prepaid royalties that come up every so often and there was about $7 million prepaid royalty that we made in December as well, so both of those obviously had a dampening effect on the cash flow. As we go into 2018 we continue to – try to target one-time adjusted net income for our free cash flow target. If you look at 2017, we had a working capital use of about $20 million and we hope to see that as a source going into next year. So we feel like we have a real opportunity on receivables and inventory to drive that. And we’re still kind of calculating what we think the impact of cash flow is at EUROIMMUN. But we still are going to shoot for the between 95% and 100% of adjusted net income.
Andy Wilson: Well, on an operating margin basis, EUROIMMUN is similar to PerkinElmer, maybe slightly higher. But the vast majority of the margin expansion is coming from core PerkinElmer.
Andy Wilson: Well, tax reform is actually going to be a bit of a headwind for us. And as I mentioned, EUROIMMUN has a higher tax rate as well, so that’s a little bit of a headwind. We said the amount coming from EUROIMMUN is 28% to 30%. So core is really growing at about 11%, and then the addition of the EUROIMMUN acquisition makes up the rest.
